Enable JavaScript to visit this website.

膽固清<sup>®</sup> Lipitor<sup>®</sup>

Lipitor

通用名稱: 阿托伐他汀鈣 (結晶型配方) Atorvastatin Calcium (Crystalline Form)

劑量: 10毫克、20毫克、40毫克、80毫克

膽固清®經多過400個臨床研究驗証、8萬多名病人參與研究及超過20年的臨床經驗,至今服用患者超過2億5千萬名1,除適合關注膽固醇人士服用,更被證實有助心血管高危族(高血壓、糖尿病及確診冠心病患者)減低心血管風險2。目前為英國國家健康與照顧卓越研究院3、美國心臟協會4及歐洲心臟病協會5多個國際指引的第一線藥物。根據一項本地醫生調查,膽固清®同時被選為「最多醫生為自己及家人選用」及「全港最多醫生認為膽固清最安全、有效」6

資料來源: 
  1. Lipitor Core Claims Document. Pfizer Corporation Hong Kong Limited: Version 3, November 2014. Data on file.
  2. Lipitor® (atorvastatin) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version September 2011.
  3. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. Available at: nice.org.uk/guidance/cg181. Accessed February 2017.
  4. Stone NJ, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation 2014;129(Suppl 2):S1-S45.
  5. Catapano AL, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016;37:2999-3058.
  6. Ipsos Healthcare 2016 Lipid Lowering Agent Preference Study Interviewed 200 HCPs (Cardiologists, Endocrinologists, Nephrologists, Neurologists and GP/OM/GOPC) in Hong Kong February – March 2016.

 

CVS17052C/MAR